Literature DB >> 12789614

Aplidin PharmaMar.

Lei Yao1.   

Abstract

Aplidin is a cell cycle inhibitor being developed by PharmaMar SA for the potential treatment of a variety of cancers, including non-Hodgkin's lymphoma (NHL), non-small-cell lung cancer (NSCLC), acute lymphoblastic leukemia (ALL), neuroendocrine, prostate, gastric and colorectal cancers [390131], [464778].

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12789614

Source DB:  PubMed          Journal:  IDrugs        ISSN： 1369-7056


  3 in total

1.  Self-Assembling Hybrid Linear-Dendritic Block Copolymers: The Design of Nano-Carriers for Lipophilic Antitumoral Drugs.

Authors:  Elisabetta Fedeli; Alexandre Lancelot; Juan Manuel Dominguez; José Luis Serrano; Pilar Calvo; Teresa Sierra
Journal:  Nanomaterials (Basel)       Date:  2019-01-29       Impact factor: 5.076

2.  Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.

Authors:  Kris M White; Romel Rosales; Soner Yildiz; Thomas Kehrer; Lisa Miorin; Elena Moreno; Sonia Jangra; Melissa B Uccellini; Raveen Rathnasinghe; Lynda Coughlan; Carles Martinez-Romero; Jyoti Batra; Ajda Rojc; Mehdi Bouhaddou; Jacqueline M Fabius; Kirsten Obernier; Marion Dejosez; María José Guillén; Alejandro Losada; Pablo Avilés; Michael Schotsaert; Thomas Zwaka; Marco Vignuzzi; Kevan M Shokat; Nevan J Krogan; Adolfo García-Sastre
Journal:  Science       Date:  2021-01-25       Impact factor: 47.728

Review 3.  Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy.

Authors:  Mariarosaria Conte; Elisabetta Fontana; Angela Nebbioso; Lucia Altucci
Journal:  Mar Drugs       Date:  2020-12-31       Impact factor: 5.118
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.